Patients Active in Research and Dialogues for an Improved Generation of Medicines (PARADIGM), is a public-private partnership with the mission to provide a unique framework that enables structured, effective, meaningful, ethical, innovative, and sustainable patient engagement (PE) and demonstrates the ‘return on the engagement’ for all players.

The objective is to develop much needed processes and tools for three key decision-making points: research priority setting, design of clinical trials and early dialogue. Building on advances at international level, PARADIGM will integrate the needs, perspectives and expectations of all actors (including vulnerable populations) involved and will also produce a set of metrics to measure the impact of patient engagement.

The Athena Institute is leader of WP3 and focusses on developing agreed patient engagement metrics to increase evidence demonstrating the impact of patient engagement practices.